You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Galmed Pharmaceuticals Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Galmed Pharmaceuticals Company Info
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
News & Analysis
These Small Cap Biopharma Stocks Lost as Much as 34.1% in October. Are They Buys?
Stock market slides are rarely kind to development-stage biopharma companies. Did October's sell-off create any opportunities for investors?
Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week
Analysts love this biotech, but should you?
3 NASH Stocks That Could Soar in the Second Half of 2018
The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.
Are These Red-Hot NASH Stocks Still a Buy?
Investors are piling into NASH stocks right now, but which ones are the best long-term buys?
Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today
Investors are cheering Galmed's experimental NASH drug, causing the biotech's shares to more than triple in value.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.